You are here: Home » News-CM » Companies » News
Business Standard

Natco Pharma launches cancer drug - Tipanat in India

Capital Market 

Natco Pharma has launched a novel fixed-dose combination of Trifluridine + Tipiracil for the first-time in India under the brand name Tipanat as a pack of 20 tablets in a bottle.

Tipanat is a novel antineoplastic nucleoside analog indicated for the treatment of advanced colorectal and gastric cancer.

In India, approximately 1,25,000 new cases of the above-mentioned cancers are reported every year.

Tipanat is of high importance in not only extending the survival but also in preserving the quality of life in the late lines of treatment which is currently an unmet medical need. NATCO has offered Tipanat at an affordable price.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, November 18 2021. 17:27 IST